The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

El Lilly’s (LLY) blockbuster weight-loss drug Zepbound is now eligible for Medicare coverage. The news could significantly ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Wegovy's success, coupled with the recognition ... has since gained approvals for obesity and other metabolic indications. Currently, semaglutide is approved for type 2 diabetes, obesity, and ...

and is in development for four additional indications, including chronic kidney disease. Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over ...

Canadian public and private insurers have balked at covering certain medication for weight-loss, but that might change as the ...

Given its low valuation and the seeming overreaction in the markets to the recent trial results, this is a stock that could ...

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

There are now seven approved GLP-1RAs. Commercially, the most successful one so far is semaglutide, sold under the brand name Wegovy or Ozempic depending on the indication.

Regeneron Pharmaceuticals, Inc. REGN provided business and pipeline updates at the 43rd Annual J.P. Morgan Healthcare ...